Venture Capital Private Equity

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

Reported by The Manila Times ·Pulse 2.0

Nov 12, 2026· 1 min read

Key Takeaways

• Hangzhou Eli Radiopharma Co., Ltd. completed a Series A financing round of nearly RMB 400 million, according to a PRNewswire release dated November 12, 2026.
• The round was led by Huagai Capital, with Bayland Capital as co-lead, and included Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management and Grand Flight Investment as new investors.
• Existing shareholders CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund and Skyfield Capital also participated.
• Proceeds will fund preclinical research, clinical trial applications and early-stage clinical development, with several programs approaching IND submission.
• The company, founded in 2024, focuses on theranostic radiopharmaceuticals for oncology and neurological diseases.

Summary

Hangzhou Eli Radiopharma Co., Ltd. (

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

2 outlets

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

The Manila Times Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

Pulse 2.0 Eli Radiopharma: Nearly $60 Million Series A Financing To Advance Radiopharmaceutical Pipeline Toward Clinical Development

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.